BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23545284)

  • 1. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
    Mohiuddin M; Paulus R; Mitchell E; Hanna N; Yuen A; Nichols R; Yalavarthi S; Hayostek C; Willett C
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):523-8. PubMed ID: 23545284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
    Mohiuddin M; Winter K; Mitchell E; Hanna N; Yuen A; Nichols C; Shane R; Hayostek C; Willett C;
    J Clin Oncol; 2006 Feb; 24(4):650-5. PubMed ID: 16446336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
    Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
    Nakamura T; Yamashita K; Sato T; Ema A; Naito M; Watanabe M
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):547-55. PubMed ID: 24929164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
    Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
    Jung M; Shin SJ; Koom WS; Jung I; Keum KC; Hur H; Min BS; Baik SH; Kim NK; Kim H; Lim JS; Hong SP; Kim TI; Roh JK; Park YS; Ahn JB
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1015-22. PubMed ID: 26581140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.
    Sanfilippo NJ; Crane CH; Skibber J; Feig B; Abbruzzese JL; Curley S; Vauthey JN; Ellis LM; Hoff P; Wolff RA; Brown TD; Cleary K; Wong A; Phan T; Janjan NA
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):176-83. PubMed ID: 11516868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
    Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
    Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Velenik V; Oblak I; Anderluh F
    Radiat Oncol; 2010 Sep; 5():88. PubMed ID: 20920276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
    Ciseł B; Pietrzak L; Michalski W; Wyrwicz L; Rutkowski A; Kosakowska E; Cencelewicz A; Spałek M; Polkowski W; Jankiewicz M; Styliński R; Bębenek M; Kapturkiewicz B; Maciejczyk A; Sadowski J; Zygulska J; Zegarski W; Jankowski M; Las-Jankowska M; Toczko Z; Żelazowska-Omiotek U; Kępka L; Socha J; Wasilewska-Tesluk E; Markiewicz W; Kładny J; Majewski A; Kapuściński W; Suwiński R; Bujko K;
    Ann Oncol; 2019 Aug; 30(8):1298-1303. PubMed ID: 31192355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
    Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
    Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
    Valentini V; Coco C; Picciocchi A; Morganti AG; Trodella L; Ciabattoni A; Cellini F; Barbaro B; Cogliandolo S; Nuzzo G; Doglietto GB; Ambesi-Impiombato F; Cosimelli M
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):664-74. PubMed ID: 12062610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
    Klautke G; Feyerherd P; Ludwig K; Prall F; Foitzik T; Fietkau R
    Br J Cancer; 2005 Apr; 92(7):1215-20. PubMed ID: 15785742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
    Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.